Welcome to our dedicated page for Lilly Eli & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Eli Lilly and Company (NYSE: LLY) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents help investors understand Lilly’s capital structure, governance, financing activities and material events affecting the business.
Lilly’s common stock and several series of notes are registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on the New York Stock Exchange, including common stock under the symbol LLY and multiple note series with maturities ranging from 2026 to 2061. Recent Form 8-K filings disclose items such as quarterly financial results furnished under Item 2.02, other events under Item 8.01, and governance changes under Item 5.02. For example, an August 2025 Form 8-K describes an underwriting agreement for floating-rate notes due 2028 and fixed-rate notes due between 2028 and 2065, while a November 2025 Form 8-K reports the election of a new independent director to Lilly’s board.
Through this page, users can review current and historical 8-Ks, along with other core filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q when available. These filings typically include details on Lilly’s therapeutic focus areas—such as cardiometabolic health, obesity, oncology, immunology and neuroscience—its risk factors, research and development programs, and financial condition.
Stock Titan enhances access to Lilly’s filings by pairing real-time EDGAR updates with AI-powered summaries. AI-generated overviews can help explain the significance of complex documents, such as new debt offerings, governance changes or major transactions, in plain language. Users can also quickly identify insider and executive-related disclosures when they appear in Forms 3, 4 or 5, and track how financing decisions, such as multi-series note issuances, fit into Lilly’s broader capital strategy.
Whether you are analyzing LLY’s latest 10-K, reviewing 10-Q trends, or examining 8-Ks related to acquisitions, collaborations and manufacturing investments, this filings hub offers a structured view of the company’s regulatory record with tools to make dense disclosures easier to interpret.
Eli Lilly and Company filed a current report to furnish its financial results for the quarter and year ended December 31, 2025. The results themselves are provided in a separate press release attached as Exhibit 99.1, dated February 4, 2026.
The company states that the information in this report, including Exhibit 99.1, is being furnished under the securities laws and is not deemed filed or subject to certain liability provisions, unless specifically incorporated by reference in other documents.
Eli Lilly executive Ilya Yuffa reported equity compensation activity involving company stock. On February 1, 2026, 3,394 restricted stock units converted into an equal number of Eli Lilly common shares at an exercise price of $0, reflecting a standard vesting event.
On the same date, 1,512.364 shares of common stock were disposed of at $1,037.15 per share in a transaction coded “F,” indicating shares withheld to cover taxes related to the vesting. After these transactions, Yuffa directly owned 28,141.607 Eli Lilly common shares.
Eli Lilly EVP Daniel Skovronsky reported equity transactions on February 1, 2026. He exercised 12,684 restricted stock units, receiving the same number of Eli Lilly common shares at an exercise price of $0 per share.
To cover related obligations, 5,641.249 common shares were withheld at a price of $1,037.15 per share. After these transactions, he directly holds 144,523.863 Eli Lilly common shares, with additional indirect holdings of 72,359 shares by a trust, 547 shares by his spouse, and 2,710 shares by his spouse's SLAT. He disclaims beneficial ownership of these reported securities except to the extent of his pecuniary interest.
Eli Lilly executive Jacob Van Naarden, EVP and President of LLY Oncology & Head of Corporate Business Development, reported equity movements in Eli Lilly common stock. On February 1, 2026, 4,108 restricted stock units were converted into the same number of common shares at an exercise price of $0, bringing his directly held common stock to 24,669.985 shares.
On the same date, 1,909.375 shares of common stock were withheld at a price of $1,037.15 per share, typically for tax obligations, leaving him with 22,760.61 shares of Eli Lilly common stock held directly. Separately, 4,342 shares are held indirectly through the Van Naarden Family Trust and 4,302 shares are held indirectly by his spouse. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Eli Lilly President, Chair, and CEO David A. Ricks reported equity award activity involving company stock on February 1, 2026. He exercised 31,932 restricted stock units, receiving the same number of Eli Lilly common shares at an exercise price of $0 per share.
On the same date, he disposed of 14,296.654 common shares at $1,037.15 per share, leaving 532,801.513 common shares held directly after the reported transactions. Additional indirect holdings are reported through several trusts, GRATs, a SLAT, and a 401(k) plan, with beneficial ownership disclaimed except to the extent of his pecuniary interest.
Eli Lilly executive Diogo Rau reported routine equity compensation activity. On February 1, 2026, 3,752 restricted stock units converted into the same number of Eli Lilly common shares at an exercise price of $0, increasing his directly held stock.
On the same day, 1,673.538 shares of common stock were withheld at a price of $1,037.15 per share, a transaction coded “F,” which typically reflects shares retained to cover taxes on vested awards. After these transactions, Rau directly owned 21,797.37 Eli Lilly common shares.
Eli Lilly executive Patrik Jonsson, EVP & President, LLY International, reported equity transactions in company stock on February 1, 2026. He exercised 3,930 restricted stock units, receiving the same number of Eli Lilly common shares at an exercise price of $0 per share.
To cover taxes from this vesting, 1,752.071 shares of common stock were withheld or disposed of at $1,037.15 per share under transaction code "F." After these transactions, Jonsson directly owned 55,828.568 shares of Eli Lilly common stock and indirectly held 608.95 shares through a 401(k) plan.
Eli Lilly and Company executive Edgardo Hernandez reported equity transactions involving company stock. On February 1, 2026, 3,572 restricted stock units converted into the same number of Eli Lilly common shares at $0 exercise price. On the same date, 1,591.452 common shares were disposed of at $1,037.15 per share.
After these transactions, Hernandez directly held 41,711.983 Eli Lilly common shares and indirectly held 871.94 shares through a 401(k) plan. Each restricted stock unit represents a contingent right to receive one Eli Lilly common share.
Eli Lilly & Co executive Anat Hakim reported routine equity transactions involving restricted stock units and common shares. On 02/01/2026, she converted 6,700 restricted stock units into Eli Lilly common stock at an exercise price of $0.
On the same date, 2,953.395 shares of common stock were withheld at a price of $1,037.15 in a transaction coded "F," typically used for tax withholding, leaving 14,709.105 common shares held directly. Additional indirect holdings are 15,700 common shares held by the Anat Hakim SLAT and 16,875 common shares held by her spouse. She disclaims beneficial ownership of these securities except to the extent of her pecuniary interest.
Eli Lilly executive Eric Dozier, EVP and Chief People Officer, reported several equity transactions dated February 1, 2026. A block of 2,858 restricted stock units converted into the same number of Eli Lilly common shares at $0 per share, increasing his direct holdings. On the same date, a disposition coded “F” covered 1,272.992 common shares at $1,037.15 per share, leaving Dozier with 11,423.918 common shares held directly. He also reports an additional 376.93 common shares held indirectly through a 401(k) account.